Loading
A phase 2 trial of Dostarlimab and Carboplatin in advanced solid tumours, run by GlaxoSmithKline, active and no longer recruiting.
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer is a phase 2 interventional study registered as NCT06317311 by GlaxoSmithKline, with 41 participants enrolled, started 2024-05-07 and due to reach its primary completion in 2026-07-15. Interventions recorded: Dostarlimab, Carboplatin and Paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Dostarlimab, GSK, Platinum agents, Carboplatin and the tag pipeline.
Shares Dostarlimab, GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/